CIA
NBIX icon

Caerus Investment Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Caerus Investment Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$254K Sell
1,509
-1,017
-40% -$151K 0.08% 243
2026
Q1 		$333K Sell
2,526
-2,726
-52% -$362K 0.14% 154
2025
Q4 		$745K Buy
5,252
+519
+11% +$75.2K 0.24% 86
2025
Q3 		$664K Buy
+4,733
New +$641K 0.27% 75

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Caerus Investment Advisors's NBIX Position: Q2 2026 in Review

Caerus Investment Advisors reduced its Neurocrine Biosciences (NBIX) stake by 40% in Q2 2026, selling an estimated $151K and leaving 1,509 shares worth $254K. The position accounts for 0.08% of the portfolio, ranked #243.

Caerus Investment Advisors first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. The position peaked at $745K in Q4 2025. 779 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Caerus Investment Advisors held 1,509 shares of Neurocrine Biosciences worth $254K as of Q2 2026.
  • Caerus Investment Advisors sold 1,017 Neurocrine Biosciences shares in Q2 2026, an estimated $151K.
  • Neurocrine Biosciences made up 0.08% of Caerus Investment Advisors's portfolio in Q2 2026, its #243 holding.
  • Caerus Investment Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • Caerus Investment Advisors's Neurocrine Biosciences position peaked at $745K in Q4 2025.
  • 779 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Caerus Investment Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.